Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL).
A. Al-Ameri
No relevant relationships to disclose
D. A. Thomas
No relevant relationships to disclose
F. Ravandi
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
H. Kantarjian
No relevant relationships to disclose
G. Borthakur
No relevant relationships to disclose
T. M. Kadia
Research Funding - GlaxoSmithKline
M. Kelly
No relevant relationships to disclose
R. Garris
No relevant relationships to disclose
S. Faderl
Research Funding - GlaxoSmithKline